Literature DB >> 2522166

Dopamine receptors in human brain: autoradiographic distribution of D1 sites.

R Cortés1, B Gueye, A Pazos, A Probst, J M Palacios.   

Abstract

The distribution of dopamine D1 receptors has been determined in post mortem human brain tissues using in vitro receptor autoradiography, with ([3H]N-methyl) SCH 23390 as ligand. The highest densities of dopamine D1 sites were seen in the nucleus caudatus, putamen, globus pallidus pars medialis and substantia nigra. Intermediate densities were associated with the amygdala, mammillary bodies, cerebral cortex and CA1. The remaining part of the hippocampus as well as the diencephalon, brainstem and cerebellum contained low levels of [3H]SCH 23390 binding sites. The distribution of D1 receptors in the human brain closely resembles that reported for the rat brain. In addition, there was a good correlation between the anatomical localization of D1 sites and the distribution of dopaminergic nerve terminals in the central nervous system. The densities of D1 receptors in the human brain were observed to markedly decrease with age during the first decades of life. However, no further modifications were found beyond the age of 40 years. We did not observe any significant influence of other parameters such as gender and post mortem delay in our samples.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522166     DOI: 10.1016/0306-4522(89)90178-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  26 in total

1.  Neuron-specific age-related decreases in dopamine receptor subtype mRNAs.

Authors:  Scott E Hemby; John Q Trojanowski; Stephen D Ginsberg
Journal:  J Comp Neurol       Date:  2003-02-03       Impact factor: 3.215

2.  Receptor alterations in manganese intoxicated monkeys.

Authors:  H Eriksson; P G Gillberg; S M Aquilonius; K G Hedström; E Heilbronn
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Age-related changes in human D1 dopamine receptors measured by positron emission tomography.

Authors:  T Suhara; H Fukuda; O Inoue; T Itoh; K Suzuki; T Yamasaki; Y Tateno
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species.

Authors:  M Camps; P H Kelly; J M Palacios
Journal:  J Neural Transm Gen Sect       Date:  1990

5.  D1- versus D2-receptor modulation of visuospatial working memory in humans.

Authors:  U Müller; D Y von Cramon; S Pollmann
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

6.  Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity.

Authors:  T A Reader; L Grondin; B Montreuil; K M Dewar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

7.  Dopamine activates noradrenergic receptors in the preoptic area.

Authors:  C A Cornil; J Balthazart; P Motte; L Massotte; V Seutin
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

8.  A mechanism underlying dopamine D1 and D2 receptor-mediated inhibition of dopaminergic neurones in the ventral tegmental area in vitro.

Authors:  T Momiyama; N Todo; M Sasa
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers.

Authors:  Mitul A Mehta; Facundo F Manes; Gianna Magnolfi; Barbara J Sahakian; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-28       Impact factor: 4.530

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.